Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis

Objectives: To evaluate the prognostic value of selected laboratory and growth markers on the short-term risk of mortality in untreated HIV-infected children in resource-limited settings. Design: A meta-analysis of individual longitudinal data on children aged 12 months onwards from 10 studies (nine African, one Brazilian in the 3Cs4kids collaboration). Methods: The risk of death within 12 months based on age and the most recent measurements of laboratory and growth markers was estimated using Poisson regression models, adjusted for cotrimoxazole prophylaxis use and study effects. Results: A total of 2510 children contributed 357 deaths during 3769 child-years-at-risk, with 81% follow-up occurring after start of cotrimoxazole. At first measurement, median age was 4.0 years (interquartile range, 2.2–7.0 years), median CD4% was 15% and weight-for-age z-score −1.9. CD4% and CD4 cell count were the strongest predictors of mortality, followed by weight-for-age and haemoglobin. After adjusting for these markers, the effects of total lymphocyte count and BMI-for-age were relatively small. Young children who were both severely malnourished and anaemic had high mortality regardless of CD4 values, particularly those aged 1–2 years. By contrast, high CD4% or CD4 cell count values predicted low mortality level amongst either children older than 5 years or those younger with neither severe malnutrition nor anaemia. Conclusions: CD4 measurements are the most important indicator of mortality and wider access to affordable tests is needed in resource-limited settings. Evaluation of antiretroviral initiation in children also needs to consider weight-for-age and haemoglobin. Prevention and treatment of malnutrition and anaemia is integral to HIV paediatric care and could improve survival.

[1]  T. Cole Babies, bottles, breasts: is the WHO growth standard relevant? , 2007 .

[2]  A. Walker,et al.  Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children , 2007, AIDS.

[3]  H. Zar,et al.  Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial , 2006, BMJ : British Medical Journal.

[4]  S. Lawn,et al.  Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study , 2006, The Lancet.

[5]  M. Newell,et al.  Within and between race differences in lymphocyte, CD4+, CD8+ and neutrophil levels in HIV-uninfected children with or without HIV exposure in Europe and Uganda , 2006, Annals of tropical paediatrics.

[6]  Veronica Mulenga,et al.  Determinants of Survival Without Antiretroviral Therapy After Infancy in HIV-1-Infected Zambian Children in the CHAP Trial , 2006, Journal of acquired immune deficiency syndromes.

[7]  T. Taylor,et al.  Observational Cohort Study of HIV-Infected African Children , 2006, The Pediatric infectious disease journal.

[8]  H. P. Study Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children , 2006, AIDS.

[9]  M. Zeier,et al.  The first 5 years of the family clinic for HIV at Tygerberg Hospital: family demographics, survival of children and early impact of antiretroviral therapy. , 2006, Journal of tropical pediatrics.

[10]  C. Giaquinto,et al.  Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data , 2005, The Lancet.

[11]  K. Maitland,et al.  Bacteremia among children admitted to a rural hospital in Kenya. , 2005, The New England journal of medicine.

[12]  N. Elenga,et al.  Respiratory manifestations in HIV-infected children pre- and post-HAART in Abidjan, the Ivory Coast. , 2004, Paediatric respiratory reviews.

[13]  Alimuddin Zumla,et al.  Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial , 2004, The Lancet.

[14]  Nigel Rollins,et al.  Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis , 2004, The Lancet.

[15]  L. Caulfield,et al.  Undernutrition as an underlying cause of child deaths associated with diarrhea, pneumonia, malaria, and measles. , 2004, The American journal of clinical nutrition.

[16]  D. Collet Modelling Survival Data in Medical Research , 2004 .

[17]  D. Dunn Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis , 2003, The Lancet.

[18]  R. Semba,et al.  Risk factors and cumulative incidence of anaemia among human immunodeficiency virus-infected children in Uganda , 2002, Annals of tropical paediatrics.

[19]  M. Newell,et al.  Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. , 2001, Pediatrics.

[20]  F. Plummer,et al.  Lymphocyte subsets in human immunodeficiency virus type 1-infected and uninfected children in Nairobi , 2001, The Pediatric infectious disease journal.

[21]  D. Hoover,et al.  Morbidity among human immunodeficiency virus-1-infected and -uninfected African children. , 2000, Pediatrics.

[22]  T J Cole,et al.  British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. , 1998, Statistics in medicine.

[23]  E. Karita,et al.  Growth of human immunodeficiency type 1-infected and uninfected children: a prospective cohort study in Kigali, Rwanda, 1988 to 1993. , 1996, The Pediatric infectious disease journal.

[24]  R. Simon,et al.  Flexible regression models with cubic splines. , 1989, Statistics in medicine.

[25]  D. Robinson,et al.  Modelling survival data in medical research, second edition , 2004 .